30464585|t|Epidural dexmedetomidine infusion for perioperative analgesia in patients undergoing abdominal cancer surgery: randomized trial.
30464585|a|OBJECTIVE: To assess the postoperative analgesic efficacy of epidural dexmedetomidine added to bupivacaine infusion for patients undergoing major abdominal cancer surgery. METHODS: Patients scheduled for major upper abdominal cancer surgery were allocated to group bupivacaine (n =32), in which patients received epidural bupivacaine infusion (6 mL/h bupivacaine 0.1%) for 48 hours postoperatively, or group bupivacaine + dexmedetomidine (n=32), in which patients received epidural dexmedetomidine added to bupivacaine infusion (6 mL/h of bupivacaine 0.1% + dexmedetomidine, 0.5 microg/mL) for 48 hours postoperatively. The cumulative morphine consumption, the time to first analgesic request, and the VAS pain score were evaluated. RESULTS: The cumulative morphine consumption was significantly reduced in group bupivacaine + dexmedetomidine compared with group bupivacaine: mean +- SD of 10.40+-5.16 mg vs 23.23+-8.37 mg with an estimated difference (95% CI) of -12.83 (-16.43, -9.24), (P<0.001). The time to the first analgesic demand was significantly delayed in group bupivacaine + dexmedetomidine compared with group bupivacaine: median (IQR) of 6 (1.75, 8.25) h vs 1 (0, 4)h, (P<0.001). The mean collapsed over time of overall VAS pain scores at rest and movement was significantly reduced in group bupivacaine + dexmedetomidine compared with group bupivacaine : mean +- SE of 1.6+-0.08 vs 2.38+-0.08 with an estimated difference (95% CI) of -0.8 (-1, -0.86), (P<0.001), and mean +- SE of 2.17+-0.07 vs 3.25+-0.07 with an estimated difference (95% CI) of -1.1 (-1.27, - 0.89), (P<0.001), respectively. CONCLUSION: Epidural infusion of dexmedetomidine added to bupivacaine for patients undergoing major abdominal cancer surgery significantly reduced morphine consumption, delayed time to first analgesic supplementation, and decreased pain intensity during the first 48 hours postoperatively without harmful derangement on hemodynamics.
30464585	9	24	dexmedetomidine	Chemical	MESH:D020927
30464585	65	73	patients	Species	9606
30464585	85	101	abdominal cancer	Disease	MESH:D009369
30464585	199	214	dexmedetomidine	Chemical	MESH:D020927
30464585	224	235	bupivacaine	Chemical	MESH:D002045
30464585	249	257	patients	Species	9606
30464585	275	291	abdominal cancer	Disease	MESH:D009369
30464585	310	318	Patients	Species	9606
30464585	345	361	abdominal cancer	Disease	MESH:D009369
30464585	394	405	bupivacaine	Chemical	MESH:D002045
30464585	424	432	patients	Species	9606
30464585	451	462	bupivacaine	Chemical	MESH:D002045
30464585	480	491	bupivacaine	Chemical	MESH:D002045
30464585	537	548	bupivacaine	Chemical	MESH:D002045
30464585	551	566	dexmedetomidine	Chemical	MESH:D020927
30464585	584	592	patients	Species	9606
30464585	611	626	dexmedetomidine	Chemical	MESH:D020927
30464585	636	647	bupivacaine	Chemical	MESH:D002045
30464585	668	679	bupivacaine	Chemical	MESH:D002045
30464585	687	702	dexmedetomidine	Chemical	MESH:D020927
30464585	764	772	morphine	Chemical	MESH:D009020
30464585	835	839	pain	Disease	MESH:D010146
30464585	886	894	morphine	Chemical	MESH:D009020
30464585	942	953	bupivacaine	Chemical	MESH:D002045
30464585	956	971	dexmedetomidine	Chemical	MESH:D020927
30464585	992	1003	bupivacaine	Chemical	MESH:D002045
30464585	1202	1213	bupivacaine	Chemical	MESH:D002045
30464585	1216	1231	dexmedetomidine	Chemical	MESH:D020927
30464585	1252	1263	bupivacaine	Chemical	MESH:D002045
30464585	1367	1371	pain	Disease	MESH:D010146
30464585	1435	1446	bupivacaine	Chemical	MESH:D002045
30464585	1449	1464	dexmedetomidine	Chemical	MESH:D020927
30464585	1485	1496	bupivacaine	Chemical	MESH:D002045
30464585	1771	1786	dexmedetomidine	Chemical	MESH:D020927
30464585	1796	1807	bupivacaine	Chemical	MESH:D002045
30464585	1812	1820	patients	Species	9606
30464585	1838	1854	abdominal cancer	Disease	MESH:D009369
30464585	1885	1893	morphine	Chemical	MESH:D009020
30464585	1970	1974	pain	Disease	MESH:D010146
30464585	Cotreatment	MESH:D002045	MESH:D020927
30464585	Negative_Correlation	MESH:D020927	MESH:D009369
30464585	Negative_Correlation	MESH:D002045	MESH:D009369
30464585	Negative_Correlation	MESH:D002045	MESH:D010146
30464585	Negative_Correlation	MESH:D009020	MESH:D020927
30464585	Negative_Correlation	MESH:D002045	MESH:D009020
30464585	Negative_Correlation	MESH:D020927	MESH:D010146

